Multinationals and Emerging Economies

Multinationals and Emerging Economies

The Quest for Innovation and Sustainability

Innovation, Co-operation and Development series

Edited by Wilfred Dolfsma, Geert Duysters and Ionara Costa

The global economy is changing rapidly and multinational corporations (MNCs) are at the forefront of this transformation. This book provides novel and profound analyses of how MNCs and emerging economies are related, and how this relationship affects the dynamics of the global economy. In particular, the authors deal with the nexus between multinationals, emerging economies and innovation from a variety of different perspectives. Innovation is regarded as a core driving force in the global economy but the authors show how it can impede as well as encourage sustainability. The book brings together insights from business studies and economics, and combines concise theoretical discussion with empirical analyses of unique data.

Chapter 4: Facing the Trial of Internationalizing Clinical Research to Developing Countries: Evidence from Mexico

Fernando Santiago-Rodríguez

Subjects: business and management, international business, organisational innovation, economics and finance, economics of innovation, international business, innovation and technology, economics of innovation, organisational innovation

Extract

Fernando Santiago-Rodríguez INTRODUCTION Recent years witness trends towards outsourcing and internationalization of clinical research by multinational pharmaceutical firms. Increasingly clinical trials are run at numerous sites around the world. Several developing countries are emerging as relevant investigative sites. Although India and China appear as preferred destinations, good prospects to participate are also available for other advanced developing economies, such as Brazil, South Africa and, as discussed here, Mexico. In addition to large domestic markets, such countries have consolidated major regional manufacturing and export bases for foreign-owned subsidiaries as well as for some domestic firms. Moreover, these emerging economies feature some country specific conditions shaping their attractiveness as investigative sites. This chapter analyses recent developments in the markets for clinical trials in developing countries. It leans on the Mexican case to illustrate some factors driving the dynamics and attractiveness of such countries as investigative sites. It also points to some challenges developing countries face to adjust and modernize their local regulatory environment governing clinical trials. The chapter brings together scholarly literature on internationalization of R&D by multinationals and on ethical implications and regulations of clinical trials. The analysis in this chapter builds on both primary and secondary data sources. Primary data were gathered through semi-structured interviews carried out in Mexico between February and August 2007. Informants included representatives from foreign-owned multinational subsidiaries and Mexican pharmaceutical firms as well as representatives from the main local trade organizations in this industry, CANIFARMA and AMIIF. The chapter also benefits from interviews with...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information